23 Oct 2015

Lantus (Insuline glargine) - France

ATC: A10AE
ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
INSULINS AND ANALOGUES FOR INJECTION, LONG-ACTING
Lantus

Generic Matches for Insuline glargine (2)
Toujeo
Abasaglar

Last Updated on 23 Oct 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Lantus Indication

Traitement du diabète sucré de l’adulte, de l’adolescent et de l’enfant à partir de 2 ans.

 

Lantus Generic Name

Insuline glargine

Type

POM

Summary Product Characteristics (SPCs) Links
Résumé des Caractéristiques du Produit - Lantus (external site)

Related Learning Zones

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Selected content related to Lantus (Insuline glargine)

Clinical Trials

News

Guidelines

Lantus Marketing Information

Lantus Generic Name
Insuline glargine
Marketing Company
Sanofi-Aventis Deutschland GmbH
Drug Type
POM
Date of Issue, Marketing Authority

09/06/2000

Médicaments utilisés en Endocrinologie et Diabète

Back to top